Sign In

Login

Password

Forgot Password ? Sign Up

RNAi-Therapeutikum (German Wikipedia)

Analysis of information sources in references of the Wikipedia article "RNAi-Therapeutikum" in German language version.

refsWebsite
Global rank German rank
8doi.org
2nd place
3rd place
4nih.gov
4th place
7th place
4web.archive.org
1st place
1st place
4zdb-katalog.de
123rd place
6th place
4europa.eu
68th place
29th place
3springer.com
274th place
152nd place
2nejm.org
2,374th place
1,391st place
2alnylam.com
low place
low place
1opko.com
low place
low place
1hemophilia.org
low place
low place
1tandfonline.com
507th place
750th place
1clinicaltrials.gov
5,225th place
2,461st place
1who.int
195th place
255th place

alnylam.com

clinicaltrials.gov

doi.org

  • Y. Zhou, C. Zhang, W. Liang: Development of RNAi technology for targeted therapy–a track of siRNA based agents to RNAi therapeutics. In: Journal of controlled release : official journal of the Controlled Release Society. Band 193, November 2014, S. 270–281, doi:10.1016/j.jconrel.2014.04.044, PMID 24816071.
  • R. Titze-de-Almeida, C. David, S. S. Titze-de-Almeida: The Race of 10 Synthetic RNAi-Based Drugs to the Pharmaceutical Market. In: Pharmaceutical research. Band 34, Nummer 7, Juli 2017, S. 1339–1363, doi:10.1007/s11095-017-2134-2, PMID 28389707.
  • M. L. Bobbin, J. J. Rossi: RNA Interference (RNAi)-Based Therapeutics: Delivering on the Promise? In: Annual review of pharmacology and toxicology. Band 56, 2016, S. 103–122, doi:10.1146/annurev-pharmtox-010715-103633, PMID 26738473.
  • H. Ledford: Drug giants turn their backs on RNA interference. In: Nature. Band 468, Nummer 7323, November 2010, S. 487, doi:10.1038/468487a, PMID 21107398.
  • David J. Kuter, Herbert L. Bonkovsky, Susana Monroy, Gayle Ross, Encarna Guillén-Navarro, Maria Domenica Cappellini, Anna-Elisabeth Minder, Ole Hother-Nielsen, Paolo Ventura, Gang Jia, Marianne T. Sweetser, Manish Thapar: Efficacy and safety of givosiran for acute hepatic porphyria: Final results of the randomized phase III ENVISION trial. In: Journal of Hepatology. Band 79, Nr. 5, November 2023, ISSN 0168-8278, S. 1150–1158, doi:10.1016/j.jhep.2023.06.013.
  • Sander F. Garrelfs, Yaacov Frishberg, Sally A. Hulton, Michael J. Koren, William D. O’Riordan, Pierre Cochat, Georges Deschênes, Hadas Shasha-Lavsky, Jeffrey M. Saland, William G. van’t Hoff, Daniel G. Fuster, Daniella Magen, Shabbir H. Moochhala, Gesa Schalk, Eva Simkova, Jaap W. Groothoff, David J. Sas, Kristin A. Meliambro, Jiandong Lu, Marianne T. Sweetser, Pushkal P. Garg, Akshay K. Vaishnaw, John M. Gansner, Tracy L. McGregor, John C. Lieske: Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1. In: New England Journal of Medicine. Band 384, Nr. 13, April 2021, ISSN 0028-4793, S. 1216–1226, doi:10.1056/NEJMoa2021712 (nejm.org [abgerufen am 15. Juli 2024]).
  • David Adams, Ivailo L. Tournev, Mark S. Taylor, Teresa Coelho, Violaine Planté-Bordeneuve, John L. Berk, Alejandra González-Duarte, Julian D. Gillmore, Soon-Chai Low, Yoshiki Sekijima, Laura Obici, Chongshu Chen, Prajakta Badri, Seth M. Arum, John Vest, Michael Polydefkis, The HELIOS-A Collaborators: Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial. In: Amyloid. Band 30, Nr. 1, 2. Januar 2023, ISSN 1350-6129, S. 18–26, doi:10.1080/13506129.2022.2091985 (tandfonline.com [abgerufen am 15. Juli 2024]).
  • Akshay S. Desai, David J. Webb, Jorg Taubel, Sarah Casey, Yansong Cheng, Gabriel J. Robbie, Don Foster, Stephen A. Huang, Sean Rhyee, Marianne T. Sweetser, George L. Bakris: Zilebesiran, an RNA Interference Therapeutic Agent for Hypertension. In: New England Journal of Medicine. Band 389, Nr. 3, 20. Juli 2023, ISSN 0028-4793, S. 228–238, doi:10.1056/NEJMoa2208391 (nejm.org [abgerufen am 15. Juli 2024]).

europa.eu

ema.europa.eu

hemophilia.org

nejm.org

  • Sander F. Garrelfs, Yaacov Frishberg, Sally A. Hulton, Michael J. Koren, William D. O’Riordan, Pierre Cochat, Georges Deschênes, Hadas Shasha-Lavsky, Jeffrey M. Saland, William G. van’t Hoff, Daniel G. Fuster, Daniella Magen, Shabbir H. Moochhala, Gesa Schalk, Eva Simkova, Jaap W. Groothoff, David J. Sas, Kristin A. Meliambro, Jiandong Lu, Marianne T. Sweetser, Pushkal P. Garg, Akshay K. Vaishnaw, John M. Gansner, Tracy L. McGregor, John C. Lieske: Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1. In: New England Journal of Medicine. Band 384, Nr. 13, April 2021, ISSN 0028-4793, S. 1216–1226, doi:10.1056/NEJMoa2021712 (nejm.org [abgerufen am 15. Juli 2024]).
  • Akshay S. Desai, David J. Webb, Jorg Taubel, Sarah Casey, Yansong Cheng, Gabriel J. Robbie, Don Foster, Stephen A. Huang, Sean Rhyee, Marianne T. Sweetser, George L. Bakris: Zilebesiran, an RNA Interference Therapeutic Agent for Hypertension. In: New England Journal of Medicine. Band 389, Nr. 3, 20. Juli 2023, ISSN 0028-4793, S. 228–238, doi:10.1056/NEJMoa2208391 (nejm.org [abgerufen am 15. Juli 2024]).

nih.gov

ncbi.nlm.nih.gov

  • Y. Zhou, C. Zhang, W. Liang: Development of RNAi technology for targeted therapy–a track of siRNA based agents to RNAi therapeutics. In: Journal of controlled release : official journal of the Controlled Release Society. Band 193, November 2014, S. 270–281, doi:10.1016/j.jconrel.2014.04.044, PMID 24816071.
  • R. Titze-de-Almeida, C. David, S. S. Titze-de-Almeida: The Race of 10 Synthetic RNAi-Based Drugs to the Pharmaceutical Market. In: Pharmaceutical research. Band 34, Nummer 7, Juli 2017, S. 1339–1363, doi:10.1007/s11095-017-2134-2, PMID 28389707.
  • M. L. Bobbin, J. J. Rossi: RNA Interference (RNAi)-Based Therapeutics: Delivering on the Promise? In: Annual review of pharmacology and toxicology. Band 56, 2016, S. 103–122, doi:10.1146/annurev-pharmtox-010715-103633, PMID 26738473.
  • H. Ledford: Drug giants turn their backs on RNA interference. In: Nature. Band 468, Nummer 7323, November 2010, S. 487, doi:10.1038/468487a, PMID 21107398.

opko.com

springer.com

adisinsight.springer.com

tandfonline.com

  • David Adams, Ivailo L. Tournev, Mark S. Taylor, Teresa Coelho, Violaine Planté-Bordeneuve, John L. Berk, Alejandra González-Duarte, Julian D. Gillmore, Soon-Chai Low, Yoshiki Sekijima, Laura Obici, Chongshu Chen, Prajakta Badri, Seth M. Arum, John Vest, Michael Polydefkis, The HELIOS-A Collaborators: Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial. In: Amyloid. Band 30, Nr. 1, 2. Januar 2023, ISSN 1350-6129, S. 18–26, doi:10.1080/13506129.2022.2091985 (tandfonline.com [abgerufen am 15. Juli 2024]).

web.archive.org

who.int

zdb-katalog.de

  • David J. Kuter, Herbert L. Bonkovsky, Susana Monroy, Gayle Ross, Encarna Guillén-Navarro, Maria Domenica Cappellini, Anna-Elisabeth Minder, Ole Hother-Nielsen, Paolo Ventura, Gang Jia, Marianne T. Sweetser, Manish Thapar: Efficacy and safety of givosiran for acute hepatic porphyria: Final results of the randomized phase III ENVISION trial. In: Journal of Hepatology. Band 79, Nr. 5, November 2023, ISSN 0168-8278, S. 1150–1158, doi:10.1016/j.jhep.2023.06.013.
  • Sander F. Garrelfs, Yaacov Frishberg, Sally A. Hulton, Michael J. Koren, William D. O’Riordan, Pierre Cochat, Georges Deschênes, Hadas Shasha-Lavsky, Jeffrey M. Saland, William G. van’t Hoff, Daniel G. Fuster, Daniella Magen, Shabbir H. Moochhala, Gesa Schalk, Eva Simkova, Jaap W. Groothoff, David J. Sas, Kristin A. Meliambro, Jiandong Lu, Marianne T. Sweetser, Pushkal P. Garg, Akshay K. Vaishnaw, John M. Gansner, Tracy L. McGregor, John C. Lieske: Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1. In: New England Journal of Medicine. Band 384, Nr. 13, April 2021, ISSN 0028-4793, S. 1216–1226, doi:10.1056/NEJMoa2021712 (nejm.org [abgerufen am 15. Juli 2024]).
  • David Adams, Ivailo L. Tournev, Mark S. Taylor, Teresa Coelho, Violaine Planté-Bordeneuve, John L. Berk, Alejandra González-Duarte, Julian D. Gillmore, Soon-Chai Low, Yoshiki Sekijima, Laura Obici, Chongshu Chen, Prajakta Badri, Seth M. Arum, John Vest, Michael Polydefkis, The HELIOS-A Collaborators: Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial. In: Amyloid. Band 30, Nr. 1, 2. Januar 2023, ISSN 1350-6129, S. 18–26, doi:10.1080/13506129.2022.2091985 (tandfonline.com [abgerufen am 15. Juli 2024]).
  • Akshay S. Desai, David J. Webb, Jorg Taubel, Sarah Casey, Yansong Cheng, Gabriel J. Robbie, Don Foster, Stephen A. Huang, Sean Rhyee, Marianne T. Sweetser, George L. Bakris: Zilebesiran, an RNA Interference Therapeutic Agent for Hypertension. In: New England Journal of Medicine. Band 389, Nr. 3, 20. Juli 2023, ISSN 0028-4793, S. 228–238, doi:10.1056/NEJMoa2208391 (nejm.org [abgerufen am 15. Juli 2024]).